VERU INC. - COMMON STO

Veru to Report Fiscal 2023 Third Quarter Financial Results on August 10, 2023

03 Aug 2023 07:30:01 By Nasdaq GlobeNewswire

Veru Inc.’s Oncology Drug Research Program Partner, The University of Tennessee Health Science Center, Awarded Two New Federal Grants

21 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

Veru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory Board

01 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

Veru to Present at the Jefferies Healthcare Conference

24 May 2023 07:30:00 By Nasdaq GlobeNewswire

Veru Reports Fiscal 2023 Second Quarter Financial Results

11 May 2023 05:30:00 By Nasdaq GlobeNewswire

Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS

04 May 2023 07:30:01 By Nasdaq GlobeNewswire

Veru Enters into Common Stock Purchase Agreement for Up to $100 Million with Lincoln Park Capital

03 May 2023 07:30:00 By Nasdaq GlobeNewswire

Veru to Report Fiscal 2023 Second Quarter Financial Results on May 11, 2023

27 Apr 2023 05:45:00 By Nasdaq GlobeNewswire

Veru Sells ENTADFI® Business for $20 Million Plus up to an Additional $80 Million from Sales Milestones

20 Apr 2023 05:45:00 By Nasdaq GlobeNewswire

Veru Enters Into Supply Agreement with Afaxys to Expand Access to FC2 Female Condom® in U.S. Public Health Sector

19 Apr 2023 07:30:20 By Nasdaq GlobeNewswire

Veru Announces Preclinical Study Results that Demonstrate Sabizabulin Inhibits Poxviruses

11 Apr 2023 07:30:00 By Nasdaq GlobeNewswire

Veru Announces Preclinical Results from Expanded Sabizabulin Program into Influenza-Induced Severe Acute Respiratory Distress Syndrome and Provides Update on COVID-19 Program

04 Apr 2023 07:30:00 By Nasdaq GlobeNewswire

Veru to Present at the Oppenheimer 33rd Annual Healthcare Conference

07 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Veru Provides FDA Update on Request for Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for ARDS

02 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Veru Reports Fiscal 2023 First Quarter Financial Results

09 Feb 2023 05:30:00 By Nasdaq GlobeNewswire

Veru to Report Fiscal 2023 First Quarter Financial Results on February 9, 2023

26 Jan 2023 07:30:00 By Nasdaq GlobeNewswire

Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board

10 Jan 2023 07:30:00 By Nasdaq GlobeNewswire

Veru Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results

05 Dec 2022 05:30:00 By Nasdaq GlobeNewswire

Veru to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results on December 5, 2022

28 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Veru Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

09 Nov 2022 19:55:21 By Nasdaq GlobeNewswire